Adlai Nortye (ANL) Current Deferred Revenue (2023 - 2024)
Adlai Nortye's (ANL) quarterly Current Deferred Revenue came in at $5.0 million in Q4 2024, little changed year-on-year from $5.0 million in Q1 2024, and little changed on a QoQ basis from $5.0 million in Q2 2024.
Adlai Nortye (ANL) Current Deferred Revenue (2023 - 2024) Analysis & Trends
Adlai Nortye (ANL) has 2 years of Current Deferred Revenue data on file, last reported at $5.0 million in Q4 2024.
- On a quarterly basis, Current Deferred Revenue changed 0.0% year-over-year to $5.0 million in Q4 2024; TTM through Dec 2024 was $5.0 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $5.0 million, changed 0.0% from the prior year.
- Current Deferred Revenue for Q4 2024 stood at $5.0 million, roughly flat from $5.0 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for ANL reached as high as $5.0 million in Q4 2023 and fell as low as $5.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Adlai Nortye | 1.16 Bn | 1.15 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Dec 31, 2023 | 5.00 Mn |